#68 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
North Carolina’s hemp industry is facing regulatory uncertainty as state officials consider whether to extend or implement a ban on hemp cultivation and sales. The article highlights the distinction between hemp (cannabis with less than 0.3% THC) and marijuana, noting that federal legalization of hemp under the 2018 Farm Bill created a thriving industry in North Carolina that now seeks protection from state-level restrictions. State regulators have expressed concerns about product quality, labeling accuracy, and the potential for hemp-derived intoxicating products to circumvent marijuana prohibitions, issues that directly affect what patients can legally access and what clinicians can safely recommend. The pending regulatory decision will determine whether patients continue to have access to hemp-derived cannabinoid products in the state and whether clinical practice standards can be established around these widely available substances. Clinicians in North Carolina should anticipate potential disruption to patient access and should now counsel patients on regulatory risks to current hemp product use while staying informed about evolving state policy.
“What we’re seeing in North Carolina is a policy gap that’s creating real clinical confusion for my patients: they can legally purchase hemp-derived products with minimal regulation, yet I have almost no reliable data on potency, contaminants, or drug interactions for the products they’re actually using. If the state allows this market to continue without standardized testing and labeling requirements, we’re essentially running an uncontrolled experiment on our population.”
🏥 As North Carolina’s hemp industry faces regulatory uncertainty, clinicians should recognize that the legal distinction between hemp (≤0.3% THC) and marijuana remains administratively fragile and may not reflect actual product potency or safety profiles available to patients. The pending ban creates a chaotic landscape where patients currently accessing hemp-derived cannabinoids through legal channels may lose access or turn to unregulated alternatives, potentially compromising product quality assurance and dosing consistency. Providers should be aware that many hemp-derived products marketed for therapeutic purposes lack rigorous clinical validation and may contain unlabeled contaminants or inconsistent cannabinoid concentrations, particularly if industry oversight weakens during transition periods. Given these regulatory gaps and the likelihood of continued product proliferation regardless of state-level restrictions, clinicians caring for patients interested in cannabinoids should maintain open, non-judgmental conversations about use, verify product sourcing when possible, and document discussions
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
